Diet, Exercise and Metformin Combination Shows Promise for Reversing Frailty in Seniors

A VA-sponsored clinical trial investigated whether combining lifestyle interventions with metformin could reverse sarcopenic obesity and frailty in older adults. This condition, characterized by simultaneous muscle loss and fat gain, significantly increases disability risk and healthcare costs in aging populations.

The randomized controlled trial enrolled 114 older Veterans with obesity and frailty markers. Participants were divided into groups receiving lifestyle therapy alone, lifestyle therapy plus metformin, or placebo controls. The lifestyle intervention included structured diet-induced weight loss and supervised exercise training.

Researchers measured changes in muscle mass, strength, physical function, and frailty indicators over the study period. The trial specifically targeted sarcopenic obesity, where individuals maintain high body weight despite losing crucial muscle tissue. This condition is particularly challenging because traditional weight loss approaches can worsen muscle loss.

Metformin, traditionally used for diabetes management, has shown promise for preserving muscle mass and improving metabolic health in aging adults. The drug may enhance exercise benefits and protect against age-related muscle decline through multiple pathways including improved insulin sensitivity and cellular energy metabolism.

While final results are pending publication, this research addresses a critical gap in treating age-related frailty. Current interventions often focus on either weight loss or muscle building separately, potentially missing synergistic benefits of combined approaches. The study's findings could inform evidence-based strategies for maintaining independence and vitality in older adults, particularly those struggling with the dual challenges of obesity and muscle loss that characterize sarcopenic obesity.